Skip to main content
. 2022 May 30;13:860784. doi: 10.3389/fphar.2022.860784

FIGURE 4.

FIGURE 4

shows the percentage of eyes with each type of retinal fluid at baseline and for each follow-up visit after switching to brolucizumab. At week 52 of treatment, the percentage of eyes with subretinal fluid (SRF) and pigment epithelial detachment (PED) decreased. However, the percentage of eyes with intraretinal fluid (IRF) was comparable between baseline and week 52 of treatment. p values refer to the statistical differences between baseline and week 52 of treatment.